Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study

Babawale, Simeon Niyi; Jensen, Tonny; Frøkjær, Jens Brøndum

doi:10.4240/wjgs.v7.i3.33

Cited by 17 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some literatures reported that more than 25% of patients diagnosed colon cancer has been spread to liver, about 25% in all patients with colorectal cancer occurred natural course of liver metastasis, and the prognosis of patients were obvious variation (Bruix et al, 2001). Other studies have also reported that the survival time of patients with colorectal liver metastasis was 23-71% in five years (Babawale et al, 2015). Main methods for treating colorectal liver metastasis including surgery, systemic chemotherapy and Transarterial chemoembolization (TACE) and radiofrequency ablation (RFA), percutaneous ethanol injection, percutaneous iodine particles implantation, etc.…”

Section: Discussionmentioning

confidence: 99%

Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases

Huang

Lv³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To evaluate efficacy of radiofrequency ablation (RFA) in treating colorectal cancer patients with liver metastases. Methods: During January 2010 to April 2012, 56 colorectal cancer patients with liver metastases underwent RFA. CT scans were obtained one month after RFA for all patients to evaluate tumor response. (CR+PR+SD)/n was used to count the disease control rates (DCR). Survival data of 1, 2 and 3 years were obtained from follow up. Results: Patients were followed for 10 to 40 months after RFA (mean time, 25±10 months). Median survival time was 27 months. The 1, 2, 3 year survival rate were 80.4%, 71.4%, 41%, 1 % respectively. 3-year survival time for patients with CR or PR after RFA was 68.8% and 4.3% respectively, the difference was statistically significant. The number of CR, PR, SD and PD in our study was 13, 23, 11 and 9 respectively. Conclusions: RFA could be an effective method for treating colorectal cancer patients with liver metastases, and prolong survival time, especially for metastatic lesions less than or equal to 3 cm. But this result should be confirmed by randomized controlled studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases

Huang

Lv³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…39 Percutaneous MWA is usually performed under ultrasound or CT guidance. 40 In comparison to other ablative techniques such as RFA, MWA produces consistently higher intertumoural temperatures, larger tumour ablation volumes, faster ablation times and less procedural pain. 39 Moreover, the heat sink effect of MWA is minimal and usually does not create ablation zone distortions in the vicinity of large blood vessels (Figure 1).…”

Section: Microwave Ablationmentioning

confidence: 99%

Current strategies in interventional oncology of colorectal liver metastases

Gruber‐Rouh

Marko

Thalhammer

et al. 2016

BJR

View full text Add to dashboard Cite

The adequate treatment of non-resectable liver metastases from colorectal cancer which are resistant to systemic chemotherapy currently provides a great challenge. The aim is to identify and review key strategies in the treatment of colorectal liver metastases. A search for current literature on the topic of interventional strategies for colorectal metastases was performed in Medline in order to achieve this goal. Studies before 2005 and with ,20 patients treated for colorectal metastases were excluded. Transarterial chemoembolization (TACE), transarterial embolization and selective internal radiation therapy (SIRT) were identified as examples of regional strategies for colorectal liver metastases, utilizing the unique blood supply of the liver. Radiofrequency ablation (RFA), microwave ablation (MWA) and cryoablation were selected as examples for currently available ablative techniques. Median survival in the key studies reviewed ranged from 7.7 to 28.6 for TACE, 8.3-12.6 for SIRT, 8.2-53.2 for RFA and 29-43 months for MWA. After review of the literature, it can be concluded that interventional oncologic therapies are a safe and effective method for treating colorectal liver metastases. The use of new chemotherapeutic agents for local therapy and new ablation technologies and techniques may increase patient survival and allows a neoadjuvant therapy setting. In addition, a combination of local therapies may be used to increase effectiveness in the future, which is subject to further research. INTRODUCTIONColorectal cancer is one of the most common cancers that shows fatal progression.1 Colorectal carcinoma most commonly metastasises to the liver due to haematogenous spread.2 At the time of diagnosis, 20-30% of patients have liver metastases, and during the course of disease, up to 60% of patients develop hepatic metastases.3 Although surgical excision is the first-line treatment for colorectal metastases, only 10-25% of patients are candidates for surgical resection. 4 Neoadjuvant systemic chemotherapy only allows 10-30% of patients with unresectable colorectal liver metastases sufficient downsizing for resection.

show abstract

“…Babawale et al reported 29% overall survival at 5 years after RFA for colorectal liver metastasis, which is comparable to our result of 27.6% overall survival at 5 years. 15 Sorensen et al and Solbiate et al, however, reported higher a 5 year overall survival of 44% and 47.8%, respectively. 13,15,25 In an European study of 426 patients who underwent RFA for HCC, Santambrogio et al reported 34% overall survival at 5 years.…”

Section: Discussionmentioning

confidence: 86%

“…15 Sorensen et al and Solbiate et al, however, reported higher a 5 year overall survival of 44% and 47.8%, respectively. 13,15,25 In an European study of 426 patients who underwent RFA for HCC, Santambrogio et al reported 34% overall survival at 5 years. 12 The median follow up interval in their study was 37.2 months (range 2-193 months).…”

Section: Discussionmentioning

confidence: 86%

“…10,11 While there have been several studies evaluating 5-year survival in small cohorts of patients undergoing RFA as part of their treatment strategy for HCC or CLM, there are only limited data on 10-year survival, which is a time interval that we believe is equivocal with cure. 3,[12][13][14][15] In this study, we sought to determine whether long-term overall survival at 10 years is obtainable in patients, who undergo RFA as part of their treatment for primary and metastatic colorectal hepatic malignancies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Sucandy

Cheek

Golas

et al. 2016

HPB

View full text Add to dashboard Cite

show abstract

Long-term survival following radiofrequency ablation of colorectal liver metastases: A retrospective study

Abstract: Our study underscores the fact that optimum patients' selection before embarking on RFA treatment is vitally important to achieving a superior outcome.

Cited by 17 publications

References 30 publications

Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases

Radiofrequency Ablation in Treating Colorectal Cancer Patients with Liver Metastases

Current strategies in interventional oncology of colorectal liver metastases

Longterm survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors

Contact Info

Product

Resources

About